Anti-TNF-Alpha Polypeptide Purification for Lower Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-TNF-alpha polypeptide compositions, such as etanercept, induce significant immunogenicity in subjects due to the formation of anti-drug antibodies, necessitating a need for a composition with reduced immunogenicity.
Innovation Solution
A composition comprising an anti-TNF-alpha polypeptide, specifically an extracellular ligand-binding portion of a human 75 kDa TNFR fused to an Fc region of human IgG1, is prepared using hydrophobic interaction chromatography (HIC) to remove impurities and aggregates, resulting in a reduced level of immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-TNF-alpha polypeptide compositions (e.g., etanercept) are administered to subjects, then therapeutic efficacy is achieved through TNF binding, but immunogenicity increases due to anti-drug antibody formation
Solution Approach 1:
The patent applies parameter changes by modifying the purification process parameters - specifically using hydrophobic interaction chromatography (HIC) with controlled salt gradients and pH conditions - to alter the composition's purity profile. This reduces immunogenicity (50-95% decrease in anti-drug antibodies) while preserving therapeutic efficacy through maintained TNF-binding capability.
2Ease of manufacture
If standard purification methods are used for anti-TNF-alpha polypeptide compositions, then manufacturing simplicity is maintained, but immunogenicity remains high due to incomplete removal of impurities and aggregates
Solution Approach 1:
The patent extracts harmful impurities and aggregates from the anti-TNF-alpha polypeptide composition using hydrophobic interaction chromatography (HIC). This extraction process specifically removes host cell proteins and aggregates that trigger immunogenicity, achieving 50-95% reduction in anti-drug antibody formation while maintaining a relatively simple two-step purification workflow.
3Stability of the object's composition
If conventional etanercept compositions are used, then established pharmacological profile is maintained, but anti-drug antibody formation occurs at significant levels
Solution Approach 1:
The patent applies preliminary action by performing hydrophobic interaction chromatography (HIC) purification before final formulation to preemptively remove immunogenic impurities and aggregates. This preliminary purification step ensures that the composition enters clinical use with reduced immunogenicity potential, preventing anti-drug antibody formation before it can compromise the established pharmacological profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves a decrease in anti-drug antibody formation by 50-95% compared to existing etanercept compositions, improving safety and efficacy.
Implementation Method 1
contacting the mixture with a hydrophobic interaction chromatography (HIC) resin, such that the anti-TNF-alpha polypeptide binds to the HIC resin
Data Source
AI summary
The invention provides a composition comprising an anti-tumor necrosis factor (TNF)-alpha polypeptide, wherein the composition produces a reduced level of immunogenicity when administered to a subject, as well as a treatment method involving the administration of the composition.